Cargando…

Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs

PURPOSE: The present study aimed to evaluate the incidence rate of radiation pneumonitis (RP) in patients with advanced lung adenocarcinoma treated with first-generation (1G), second-generation (2G), or third-generation (3G) epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) com...

Descripción completa

Detalles Bibliográficos
Autores principales: Mu, Fengchun, Fan, Bingjie, Li, Butuo, Qin, Wenru, Li, Haoqian, Wang, Chunni, Zou, Bing, Wang, Shijiang, Wang, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106805/
https://www.ncbi.nlm.nih.gov/pubmed/37077536
http://dx.doi.org/10.2147/CMAR.S404874
_version_ 1785026487518232576
author Mu, Fengchun
Fan, Bingjie
Li, Butuo
Qin, Wenru
Li, Haoqian
Wang, Chunni
Zou, Bing
Wang, Shijiang
Wang, Linlin
author_facet Mu, Fengchun
Fan, Bingjie
Li, Butuo
Qin, Wenru
Li, Haoqian
Wang, Chunni
Zou, Bing
Wang, Shijiang
Wang, Linlin
author_sort Mu, Fengchun
collection PubMed
description PURPOSE: The present study aimed to evaluate the incidence rate of radiation pneumonitis (RP) in patients with advanced lung adenocarcinoma treated with first-generation (1G), second-generation (2G), or third-generation (3G) epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with thoracic radiotherapy (TRT). PATIENTS AND METHODS: Patients with advanced lung adenocarcinoma simultaneously treated with 1G/2G/3G EGFR-TKIs and TRT between 2015–2021 at Shandong Cancer Hospital and Institute were screened. The incidence rate of clinical and imaging RP was compared between the three groups. RESULTS: A total of 200 patients treated with EGFR-TKIs were enrolled in this study, including 100 patients who were treated with 1G EGFR-TKIs, 50 patients who were treated with 2G EGFR-TKIs, and 50 patients who were treated with 3G EGFR-TKIs (patients matched in a 2:1:1 ratio for tumor characteristics). The overall incidence of clinical RP in the 1G, 2G, and 3G EGFR-TKI groups were 29%, 48%, and 28% (p=0.043), respectively, and that of imaging RP were 33%, 58%, and 36% (p=0.010), respectively. The incidence of RP with a clinical grade ≥3 in the three groups were 14%, 28%, and 12% (p=0.055), respectively, and that with an imaging grade ≥3 in the three groups were 11%, 32%, and 10% (p=0.002), respectively. The incidence of clinical RP was higher in the CFRT group than in the SBRT group, with an overall clinical grade of 38% vs 10% (p<0.001) and imaging grade of 46% vs 10% (p<0.001), respectively. In the multivariate analysis, only GTV volume was an independent predictive factor for all risks of clinical and imaging RP. V20 and grouping of 1G/2G/3G EGFR-TKIs were other independent predictive factors for the risk factors of RP for imaging grades. CONCLUSION: Compared with 2G EGFR-TKIs combined with TRT, 1G or 3G EGFR-TKIs combined with TRT achieved a lower incidence of RP.
format Online
Article
Text
id pubmed-10106805
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-101068052023-04-18 Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs Mu, Fengchun Fan, Bingjie Li, Butuo Qin, Wenru Li, Haoqian Wang, Chunni Zou, Bing Wang, Shijiang Wang, Linlin Cancer Manag Res Original Research PURPOSE: The present study aimed to evaluate the incidence rate of radiation pneumonitis (RP) in patients with advanced lung adenocarcinoma treated with first-generation (1G), second-generation (2G), or third-generation (3G) epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) combined with thoracic radiotherapy (TRT). PATIENTS AND METHODS: Patients with advanced lung adenocarcinoma simultaneously treated with 1G/2G/3G EGFR-TKIs and TRT between 2015–2021 at Shandong Cancer Hospital and Institute were screened. The incidence rate of clinical and imaging RP was compared between the three groups. RESULTS: A total of 200 patients treated with EGFR-TKIs were enrolled in this study, including 100 patients who were treated with 1G EGFR-TKIs, 50 patients who were treated with 2G EGFR-TKIs, and 50 patients who were treated with 3G EGFR-TKIs (patients matched in a 2:1:1 ratio for tumor characteristics). The overall incidence of clinical RP in the 1G, 2G, and 3G EGFR-TKI groups were 29%, 48%, and 28% (p=0.043), respectively, and that of imaging RP were 33%, 58%, and 36% (p=0.010), respectively. The incidence of RP with a clinical grade ≥3 in the three groups were 14%, 28%, and 12% (p=0.055), respectively, and that with an imaging grade ≥3 in the three groups were 11%, 32%, and 10% (p=0.002), respectively. The incidence of clinical RP was higher in the CFRT group than in the SBRT group, with an overall clinical grade of 38% vs 10% (p<0.001) and imaging grade of 46% vs 10% (p<0.001), respectively. In the multivariate analysis, only GTV volume was an independent predictive factor for all risks of clinical and imaging RP. V20 and grouping of 1G/2G/3G EGFR-TKIs were other independent predictive factors for the risk factors of RP for imaging grades. CONCLUSION: Compared with 2G EGFR-TKIs combined with TRT, 1G or 3G EGFR-TKIs combined with TRT achieved a lower incidence of RP. Dove 2023-04-12 /pmc/articles/PMC10106805/ /pubmed/37077536 http://dx.doi.org/10.2147/CMAR.S404874 Text en © 2023 Mu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Mu, Fengchun
Fan, Bingjie
Li, Butuo
Qin, Wenru
Li, Haoqian
Wang, Chunni
Zou, Bing
Wang, Shijiang
Wang, Linlin
Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
title Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
title_full Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
title_fullStr Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
title_full_unstemmed Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
title_short Comparison of the Incidence Rate of Radiation Pneumonitis Observed in Patients with Advanced Lung Adenocarcinoma Treated with Simultaneous Thoracic Radiotherapy and 1G/2G/3G EGFR-TKIs
title_sort comparison of the incidence rate of radiation pneumonitis observed in patients with advanced lung adenocarcinoma treated with simultaneous thoracic radiotherapy and 1g/2g/3g egfr-tkis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106805/
https://www.ncbi.nlm.nih.gov/pubmed/37077536
http://dx.doi.org/10.2147/CMAR.S404874
work_keys_str_mv AT mufengchun comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis
AT fanbingjie comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis
AT libutuo comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis
AT qinwenru comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis
AT lihaoqian comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis
AT wangchunni comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis
AT zoubing comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis
AT wangshijiang comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis
AT wanglinlin comparisonoftheincidencerateofradiationpneumonitisobservedinpatientswithadvancedlungadenocarcinomatreatedwithsimultaneousthoracicradiotherapyand1g2g3gegfrtkis